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Abstract. In the present study, we sought to elucidate the effect
of miR‑145 on glioma cell progression and its mechanisms of
action. We examined the effects of miR‑145 on proliferation
and invasion of U87 glioma cells and on capillary tube formation. Our data show that restoration of miR‑145 in U87 glioma
cells significantly reduced their in vitro proliferation, invasion
and angiogenesis. However, decreased miR‑145 expression
promoted U87 glioma cell proliferation, invasion and angiogenesis, and reduced-expression of miR‑145 increased ADAM17
and EGFR expression in U87 cells. Overexpression of miR‑145
reduced ADAM17 and EGFR expression. VEGF secretion
and VEGF expression were decreased by increased miR‑145
expression in U87 cells and were reversed by miR‑145 downregulation in vitro. Nude mice with intracerebral implantation
of U87 overexpressing miR‑145 cells exhibited significantly
reduced tumor growth and promoted survival compared with
control groups. Taken together, these results suggest a role
for miR‑145 as a tumor suppressor which inhibits glioma cell
proliferation, invasion and angiogenesis in vitro and reduces
glioma growth in vivo.
Introduction
High-grade gliomas are malignant as they are highly vascularized and invasive, and characterized by high incidence of
recurrence and poor prognosis (1,2). The prognosis for patients
with malignant gliomas has not significantly changed in recent
years (3). Glioma cells infiltrate into the normal brain adjacent to the tumor causing treatment failure from conventional
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therapy, including surgery, radiotherapy and chemotherapy
(4). Thus, median survival time has changed little and is ~15
months (1). Brain tumors constitute the second most frequent
cause of cancer deaths in patients <15 years of age, the thirdcause for adult men, and the fourth cause in women aged 15-34
years (5). Malignant gliomas are highly fatal and often strike
patients in their most productive years.
MiRNAs, a class of small, non-encoding RNAs that transcriptionally or post- transcriptionally modulate the expression
of their target genes, and have been implicated as regulatory
molecules in various cancers from lung, breast, colon, prostate, head and neck, including melanoma and glioma (6,7).
MiRNAs may alter the functions of oncogenes and/or tumor
suppressor genes, and therefore, impact the biological behavior
of these cancers. miR‑145 is a tumor-suppressive miRNA that
has been recently implicated in the regulation of cell growth
in tumor cells through targeting c-myc, EGFR, OCT4, and
MUC1 (8-11). However, little has been reported on whether
miR‑145 is associated with glioma progression.
ADAM17 (a.k.a. TACE), is involved in the ectodomain
shedding of multiple membrane-bound ligands and cytokines, it has been implicated in diverse biological processes,
including growth and inflammation (12). Currently, ADAM17
is best known as the primary secretase responsible for releasing
the soluble form of tumor necrosis factor- α (TNF- α) from
the plasma membrane. Of particular interest, ADAM17 has
recently been identified as the primary sheddase for multiple
epidermal growth factor receptor (EGFR) pro-ligands (13).
EGFR ligand-binding results in receptor self-dimerization,
auto-phosphorylation and subsequent activation of downstream
PI3K/AKT and Ras/MAPK/ERK signaling pathways (14-16).
EGFR is the prototype of a family of receptors with tyrosine
kinases that participate in the control of differentiation, proliferation, and cell survival, as well as in the development of
tumors of epidermal origin (16-19). The expression of EGFR
is frequently upregulated in human glioma, and its overexpression correlates with poor prognosis (19).
Recently, we have demonstrated that expression of miR‑145
is significantly downregulated in glioma cells as compared
with normal brain tissue (20). miR‑145 directly targets
ADAM17 and binds to 3' UTR of ADAM17 mRNA, decreasing
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ADAM17 protein expression. Our present study demonstrates
that overexpression of miR‑145 inhibits glioma cell proliferation, invasion, angiogenesis in vitro, and decreases glioma cell
growth in an animal model, possibly through the mechanism
of miR‑145-related decrease of ADAM17 and EGFR protein
expressions via the Erk/p-Erk pathway in U87 cells.
Materials and methods
Cell line and cell culture. Human glioblastoma U87, and mouse
brain endothelial cells were obtained from the American Type
Culture Collection (Manassas, VA, USA). The cells were
grown in Dulbecco's modified Eagle's medium (DMEM;
Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum, 50 U/ml penicillin, and 50 mg/ml streptomycin.
The U87 cells were maintained in a humidified 37˚C incubator
with 5% CO2, fed every 3 days with complete medium, and
subcultured when confluence was reached.
Transfection of U87 cells with miR‑145 and MiRzip‑145. The
cDNAs encoding miR‑145 and cel-67 were purchased from
Genscript (Piscataway, NJ, USA). MiRzip‑145 was purchased
from System Biosciences (Mountain View, CA, USA).
Transfections were done with the use of Lipofectamine 2000
(Life Technologies, Grand Island, NY, USA) according to
the manufacturer's instructions. Briefly, 1.5x105 U87 glioma
cells were seeded onto 6-well plate and incubated with 4 µg
cDNA as suggested by the manufacturer. After 48 h, cells
were selected using Puromycin (Sigma-Aldrich, St. Louis,
MO, USA).
Modified cell lines. Modified cell lines used in this study
were stable transfection U87 cells with miR‑145 cDNA
plasmid stable transfection (U87-miR‑145), U87 glioma cells
with negative control cel-67 plasmid (U87-cel-67), and U87
glioma cells with miRzip‑145 (targeting miR‑145) plasmid
stable transfection (U87-zip‑145). The stable transfection was
completed per the instructions of the Lipofectamine 2000 kit,
according to the manufacturer's instructions.
Growth curve. U87 cells (1x104) were plated into each well of
24-well plates containing DMEM with FBS at a concentration of 10%. Every 24 h medium was removed, adherent cells
were trypsinized, and the total cell number of each well was
quantified with the use of a hematocytometer. Cell number
was expressed as an average of counts from three wells per
time point per group.
Bromodeoxyuridine incorporation assay. Cell proliferation
was measured using BrdU incorporation assay. Forty thousand
cells in 1,000 µl complete medium per well were placed into
24-well plates. After 48-h incubation, the culture medium was
removed and cells were rinsed with PBS followed by incubation
with BrdU (25 µg/ml) for 2 h and fixed in 4% paraformaldehyde for 30 min at room temperature. Following fixation, cells
were incubated with 50% formaldehyde in 2X SSC at 65˚C for
30 min and with 2N HCl at 37˚C for 10 min. After incubation
with 0.1 M boric acid at room temperature for 3 min, cells were
rinsed with PBS and blocked with 1% bovine serum albumin
at room temperature for 1 h, followed by incubation with an

anti-BrdU antibody overnight at 4˚C. Cells were then incubated with a FITC-conjugated secondary antibody to visualize
BrdU positive labeled cells. Before mounting with coverslips,
cells were incubated with 10 µg/ml of DAPI (4'-6-diamidino2-phenylindole, Invitrogen) for 10 min. Four fields of cells were
counted randomly in each well under a fluorescent microscope
at x10 magnification. The proliferation rate was expressed as
the percentage of BrdU positive labeled cells divided by DAPI
labeled cells.
In vitro invasion assay. Matrigel chambers (BD Biosciences)
were used to determine the effect of stable expression of
miR‑145 on invasiveness, according to the manufacturer's
protocol. Cells (1x105) with stable transfection of miR‑145, or
zip‑145 were plated into 6-well plates and incubated for 48 h.
Then, glioma cells were re-suspended in 500 µl of serum-free
medium and added to the upper chamber, while the lower
chamber was filled with 0.5 ml of complete medium that
served as a chemo-attractant. Cells were then incubated for
24 h at 37˚C. After removal of cells from the upper surface
of the membrane, cells on the lower surface of the membrane
were stained with CellTracker™ Green (Molecular Probes,
Eugene, OR, USA) for 30 min and fixed in 4% formaldehyde.
Nine fields of cells were counted randomly in each well
under a fluorescent microscope at x100 magnification. All the
experiments were done in duplicate and results were expressed
as mean ± SEM of three independent experiments.
Capillary-like tube formation assay. Briefly, 0.1 ml growth
factor reduced Matrigel (Becton-Dickinson) was added per
well, and mouse brain endothelial cells (MBECs, 2x104 cells)
were added and incubated in: i) regular cell culture medium
(DMEM) for control; ii) cell culture medium from U87 only
cell culture; iii) cell culture medium from U87 miR‑145 cell
culture; iv) cell culture medium from U87 zip‑145 for ≤3 h.
All assays were performed in triplicates. For quantitative
measurements of capillary tube formation, Matrigel wells were
digitized under a 4x objective (Olympus) for measurement of
total tube length of capillary tube formation using the MCID
image analysis system (Imaging Research, St. Catharines,
Canada) at 3 h. Tracks of endothelial cells organized into
networks of cellular cords (tubes) were counted and averaged
in randomly selected three microscopic fields. The total tube
length was calculated by MCID software in each field. The
tube formation index was expressed as tube length (mm)
per field.
Western blot analysis. Cultures were rinsed with PBS and
proteins were extracted in 500 ml RIPA lysis buffer (50 mM
Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1 mM EDTA, 0.1% SDS and 0.01% sodium azide,
pH 7.4). Equal amounts of proteins, as determined by the BCA
protocol (Pierce, Rockford, IL, USA), run on 10% Tris-glycine
gels (Invitrogen) and then transferred to PVDF membranes
(Bio-Rad, Hercules, CA, USA). The membranes were blocked
with 0.1% I-Block (Applied Biosystems, Foster City, CA,
USA) in PBS-T (0.3% Tween-20) at room temperature for
1 h, followed by incubation with primary antibodies against
ADAM17 (Abcam, Cambridge, MA, USA), EGFR (Cell
Signaling, Danvers, MA, USA), Erk, p-Erk and actin (Santa
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Cruz, Santa Cruz, CA, USA) at 4˚C overnight. The membranes
were washed with PBS-T (0.3% Tween-20) and incubated for
1 h at room temperature with horseradish peroxidase-conjugated secondary antibodies (Bio-Rad Laboratories). Following
washing, the specific proteins were detected using a West Pico
chemiluminescent protein detection kit (Pierce). The experiment was repeated in triplicate. The densities of the bands
were analyzed using the Scion image software (Frederick,
MD, USA).
TaqMan real-time PCR analysis of miR‑145. Extraction of
total RNA was obtained using Qiagen miRNeasy Mini isolation kit (Qiagen, Valencia, CA, USA) in accordance with the
manufacturer's instructions. To quantify the expression level
of the miR‑145 in glioma cells with either stable transfection of
miR‑145 or zip‑145, TaqMan real-time PCR of miR‑145 expression was carried out using TaqMan assay kits according to the
manufacturer's protocol. The kits contain TaqMan probes to
detect mature miRNA in a two-step RT-PCR analysis. CDNAs
were synthesized from total RNA using miRNA-specific
primers and the TaqMan miRNA reverse transcription (RT)
kit, according to the manufacturer's instructions. The 15-µl
reactions were incubated on a PCR system for 30 min at 16˚C,
30 min at 42˚C, 5 min at 85˚C, and then held at 4˚C. All reverse
transcriptions and no-template controls were run at the same
time. PCR amplification was carried out using sequencespecific primers on the Applied Biosystems 7500 real-time
PCR system (Applied Biosystems). The assay was carried
out in a 96-well optical plate at 95˚C for 10 min, followed by
40 cycles of 95˚C for 15 sec and 60˚C for 60 sec. The threshold
cycle (CT) data and baselines were determined using auto
settings. U6 small RNA (RNU6B) was also identified using
the TaqMan RNU6B assay kit for normalizing the levels of
miR‑145. Each sample that included no template was analyzed
in triplicate.
Human glioma cell implantation in nude mice. Nude mice
(Nu/Nu Athymic, Charles River Breeding, MA, USA) with
body weight of 15-25 g were anesthetized with ketamine
(80 mg/kg) and xylazine (10 mg/kg) administered intraperitoneally (i.p.). After fixing the mouse in a stereotaxic device,
the scalp was retracted to expose the cranium, and a 3-4-mm
incision was made directly down the midline. With the use of
a drill, a 2-mm craniotomy was made on the right hemisphere
anterior to the coronal suture. A 10-ml Hamilton syringe was
positioned to inject tumor cells stereotactically into the right
hemisphere - 3.5 mm depth, 1.5 mm to the right, and 1.0 mm
anterior to the bregma. U87 cells (7.5x105), U87-cel‑67,
U87-miR-15, or U87-zip‑145 were injected intracerebrally in
a 7.5-µl volume. The craniotomy was covered with a film of
polyvinyl chloride glued to the surrounding intact bone and
the incision was closed with 4-0 silk suture. Tumor volume
was evaluated in 6-mm paraffin sections in the tumor region
stained with H&E. During sacrifice, mice were perfused via
the left ventricle with heparinized saline followed by 4% paraformaldehyde. Tumor-bearing brain was processed, placed in
paraffin, and subsequently five equally spaced sections (6 mm
thick) were obtained from each of the 1-mm thick blocks
encompassing the tumor. The sections were stained with H&E
for microscopic analysis.

1033

Statistical analysis. Data are presented as mean and standard
error of the mean. Statistical significance was analyzed by
one-way ANOVA using GraphPad Prism software (version 4.0).
P-value smaller than 0.05 (P<0.05) was considered statistically
significant.
Results
miR‑145 expression level in human glioma cell lines. Using
real-time RT-PCR, we compared the expression levels of
miR‑145-3p and miR‑145-5p in glioma cell lines with total
RNA from normal human astrocytes. Human astrocytes were
obtained from ScienCell Research Laboratories. As shown
in Fig. 1, miR‑145-5p and miR‑145-3p expression levels were
significantly lower (4.2 and 6.3%) in U87 compared to total
RNA from human astrocytes. miR‑145-5p directly targets
ADAM17 mRNA and inhibits glioma cell proliferation and
invasion (20). These data suggest the potential therapeutic
value of miR‑145 in malignant human gliomas.
Establishment of U87 with stable expression of miR‑145 and
its inhibitor zip‑145. We transfected U87 glioma cells with
plasmids encoding miR‑145 or zip‑145, then added puromycin
for high-expression clones. To determine miR‑145 expression
level with stable transfection of miR‑145 and its inhibitor
zip‑145, Taqman real-time PCR analysis of miR‑145 level was
used to measure and confirm miR‑145, zip‑145 versus control
U87 cells. As shown in Fig. 1, miR‑145 expression level was
significantly elevated (53.8-fold) in U87-145 cells compared
with levels in control U87 cells. As for miR‑145 overexpression in U87-zip‑145 glioma cells, Fig. 1 shows that miR‑145
expression level was significantly decreased to 0.4% compared
to control U87 cells. The data suggested that stable transfection of miR‑145 and zip‑145 was established in the U87 cell
lines.
miR‑145 decreases cell growth in U87 glioma cells. U87 cells
transfected with miR‑145 plasmid and control U87 cells
were harvested and seeded at a density of 1x10 4 cells/well
in 24-well plates. The total cell number was quantified daily
with a hematocytometer. Our data showed that overexpression of miR‑145 significantly decreased the growth rate of
U87 cells after 5 days culture (Fig. 2). Downregulation of
miR‑145 significantly increased the growth rate of U87 cells
from 13.2 to 20.3% compared to control. We employed an
additional method, the BrdU incorporation assay, to further
test miR‑145-mediated growth inhibition of glioma cells using
miR‑145 plasmid transfected U87 clones (Fig. 2). After 48 h of
culture, miR‑145 cells showed a 47.7% decrease in BrdU incorporation as compared with control. At the same time, we tested
the downregulation of miR‑145 on glioma cell proliferation.
As compared with control U87 cells, miR‑145 downregulation
evidently increased BrdU incorporation after 48 h of culture
by 145.4% as compared with the control group.
Overexpression of miR‑145 inhibits glioma cell invasive‑
ness. We employed the Matrigel invasion assay to test if
overexpressing miR‑145 affects glioma cell invasiveness.
Invasive cells were measured at 24 h after addition of cells
into the upper chamber. miR‑145 overexpression significantly
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A

B

Figure 1. miR‑145 expression levels in glioma cells. (A) Total RNA was isolated from normal human astroyctes and U87 gliomas. Real-time PCR was
performed to analyze the expression ofmiR‑145-3p and miR‑145-5p. The relative expression of miR‑145-3p and-5p was expressed as the ratio of the expression
level of normal human astrocytes. *P<0.05, as compared with norml human astrocytes. (B) U87 glioma cells were stably transfected with miR‑145 and zip‑145,
and collected for real-time RT-PCR. Stable transfection of miR‑145 significantly increased miR‑145-5p in U87, as compared with non-transfected cells.
However, compared to non-transfected U87 cells, stable transfection of zip‑145 significantly decreased miR‑145-5p. *P<0.05 versus U87 glioma cells without
transfection of miR‑145 or zip‑145.

A

B

Figure 2. miR‑145 inhibits glioma cell growth and proliferation in vitro. Overexpression decreased glioma proliferation. Downregulation of miR‑145 by
zip‑145 increased glioma cell proliferation. (A) Growth curve; (B) BrdU incorporation assay for 48 h. *P<0.05 versus control.

decreased cell invasion by 63.6% in U87 (Fig. 3). However,
the invasiveness of miRzip‑145 transfected glioma cells was
significantly increased by 1.53-fold compared to control cells.
The in vitro invasion assay data indicated that the invasiveness
of U87 glioma cells is related to miR‑145 expression levels, and
increase of miR‑145 decreases the invasiveness in U87 cells.
Overexpression of miR‑145 inhibits tube formation in cultured
mouse brain endothelial cells. To test the effect of miR‑145
expression upon glioma-induced angiogenesis, we performed
a tube-formation assay of mouse brain endothelial cells
(MBECs) in vitro. As shown in Fig. 4, culture medium from
U87 glioma overexpressing miR‑145 significantly reduced
capillary tube formation of mouse brain endothelial cells by
34.55% when compared to control U87 media. While downregulation of miR‑145 medium showed a significant 1.28-fold
increase in MBECs capillary tube formation compared to

control medium. These results suggest that miR‑145 in glioma
cells promotes angiogenesis.
Overexpression of miR‑145 decreases VEGF in mRNA and
soluble protein release levels. Real-time PCR was employed
to measure VEGF mRNA expression level in U87 miR‑145,
U87 zip‑145, and control U87 glioma cells (Fig. 4). VEGF
expression level was significantly increased (3.16-fold) in U87
zip‑145 cells, and was significantly decreased by 95.13% in
U87 miR‑145 cells compared to control cells. These results
indicate that miR‑145 regulates VEGF mRNA expression.
VEGF soluble protein release showed the same profile
as mRNA levels in all experimental groups. miR‑145,
zip‑145, control U87 cells were cultured under 37˚C for 24 h
to attached to the bottom of the 6-well plate, respectively.
Following complete removal of medium 24 h later, glioma
cells were rinsed by PBS and serum-free medium was added
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Figure 3. Effect of miR‑145 expression on glioma cell invasiveness in vitro. The 24-h in vitro Matrigel invasion assay revealed that miR‑145 overexpression
decreased glioma cell invasiveness by 63.6% compared to control cells, and the miR‑145 downregulation significantly increased invasiveness by 1.53-fold
compared to control cells. In vitro invasion assay indicated that the invasiveness of U87 glioma cells is correlated to miR‑145 levels. *P<0.05 versus control.

Figure 5. Effect of miR‑145 overexpression or downregulation on ADAM17/
EGFR/ERK activation in U87 cells. miR‑145 was reported to directly target
ADAM17 and EGFR. ADAM17 and EGFR expression showed a significant
decrease in U87 miR‑145 cells and a significant increase in U87 zip‑145 cells.
Expression of p-Erk showed the same trend as ADAM17/EGFR, but expression of Erk was not significantly affected by miR‑145 expression levels.

Figure 4. miR‑145 overexpression in glioma cells inhibits tube formation in
MBECs. Culture medium from U87 miR‑145 cells decreased MBECs capillary
tube formation by 34.55% compared to control medium. Medium from U87
zip‑145 cells promoted capillary tube formation by 1.28-fold compared to control. As compared with medium only, U87 conditioned medium increased the
tube formation in MBECs. Overexpression of miR‑145 signficantly decreased
VEGF expression in U87 miR‑145 cells and soluble VEGF release after 24 h.
While zip‑145 significantly promoted VEGF expression in U87 zip‑145 cells
and soluble VEGF release. *P<0.05 versus control; **P<0.05 versus control.

for another 24 h. Culture medium was then collected for analysis of soluble VEGF release from glioma cells (Fig. 4). High
miR‑145 expression decreased to 62.4% the VEGF release to
supernatant by U87 miR‑145, and low expression of miR‑145
increased VEGF release to 2.4-fold by U87 zip‑145.
ADAM17, EGFR, and Erk phosphorylation in miR‑145 over‑
expressing cell lines. To test the hypothesis that ADAM17/
EGFR/ERK/p-ERK contribute to the miR‑145 effect on
glioma cells, western blot assay was employed (Fig. 5). The
data showed that miR‑145 overexpressing U87 cells have
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Figure 6. The expression level of miR‑145 is related to U87 glioma cell growth in nude mice. U87 miR‑145 showed significant decrease in tumor volume
(36.25 vs 1.25 mm3, *P<0.05) in nude mice compared to control glioma cells. Zip‑145 transfected cells showed no significant growth rate as compared with
their parent cells. n=6 nude mice/group; *P<0.05 versus control.

lower expression of ADAM17 and EGFR, respectively, in
total protein levels, and lower phosphorylation state of Erk as
compared with control groups. Furthermore, low expression of
miR‑145 in glioma cells was correlated to increased ADAM17
and EGFR expression. These data suggest that miR‑145
significantly contribute to the pathways known to promote
glioma cell malignancy.
miR‑145 inhibits U87 glioma growth in nude mice. MiR145overexpressing U87 glioma cells were transfected with
negative plasmid cel-67, and: i) control; ii) cel-67; iii) miR‑145;
and iv) zip‑145 U87 glioma cells were injected stereotactically
(5x105 cells/mouse) at a depth of 3.5 mm, 1.5 mm to the right
of midline, and 1.0 mm anterior to the bregma. Animals were
sacrificed at 30 days after tumor implantation. Tumor-bearing
brain was processed, placed in paraffin, and subsequently
seven equally spaced, 6 µm sections, were obtained from each
of the 1-mm blocks encompassing the tumor. The sections
were stained with H&E for light microscopic examination and
analysis. After 30 days, miR‑145 transfected U87 cells showed
a significant decrease in tumor volume (Fig. 6) in nude mice
compared to control cells and parent glioma cells transfected
with cel-67. As shown in Fig. 6, zip‑145 transfected U87 cells
grew to form a solid tumor and showed no significant increase
in tumor volume in comparison with control. The nude mice
with U87 zip‑145 cell implantation died 14 days after implantation. These data indicate that miR‑145 significantly contributes
to glioma xenograph growth, and suggests overexpression of
miR‑145 may have therapeutic antitumor effects for glioma.
Discussion
Glioblastoma is the most common primary brain tumor in
adults. Almost all high-grade gliomas will invariably recur due
to their extensive invasion into the surrounding brain tissue
supported by their high capacity of neovascularization (21).
These features cause treatment failure and have a very high
mortality rate by conventional therapies. ADAMs are an
important family of proteins upregulated in many cancers

including glioma (22,23). miR‑145 has been reported to target
and regulate ADAM17, an important ADAM family member
(20,24). In addition, accumulated evidence showed that the
non-coding miRNAs have multi-function on gene regulation
during tumor progression (25).
In the present study, the U87 human glioblastoma cell
line was employed to investigate to the effect of miR‑145 on
glioma cell proliferation, invasion, and angiogenesis in vitro.
Overexpression and downregulation of miR‑145 were established with transfection of miR‑145 and zip‑145 plasmids,
respectively. Growth curve and BrdU incorporation assays
were employed to examine the effect of miR‑145 on U87
glioma cell proliferation. Our data demonstrate that miR‑145
decreases U87 glioma cell proliferation. Decrease of miR‑145
by zip‑145 significantly increased tumor cell proliferation.
These data suggest that miR‑145 plays a key role in U87 cell
malignancy. We used Matrigel invasion assays to assess the
ability of glioma cells to penetrate the ECM. Our data showed
that the invasion potential of U87 cells is decreased by miR‑145
overexpression, and increased by miR‑145 downregulation.
Neovascularization plays critical roles in the process
of embryo development, tissue differentiation and repair,
inflammatory diseases, and tumor growth and metastasis
(26,27). During the angiogenic process, endothelial cells
digest the basement membrane of the vessel, migrate through
the membrane while they proliferate in number, form a new
vessel lumen and then sprout into a new vessel branch (28).
Proliferation and growth of tumor cells consume oxygen in
solid tumors. The hypoxia and necrosis resulting from rapid
growth triggers the angiogenic switch out of the vascular
quiescent state, which subsequently supports tumor progression (29). The initiation of newly formed tumor vessels also
known as neovascularization or angiogenesis requires proangiogenic growth factors including vascular endothelial
growth factor (VEGF) and related molecules. VEGF can be
triggered by extracellular signals such as transforming growth
factor α (TGF-α) and hypoxia-inducible factor 1-α (HIF-α),
and internal genetic change (29,30). ADAM17 and EGFR
increase the expression of HIF-α, and HIF-α then activates
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VEGF and VEGFR to stimulate tumor angiogenesis (22,31).
To address the function of miR‑145 on glioma angiogenesis,
we further tested VEGF expression in U87 cells and angiogenesis in vitro with mouse brain endothelial cells cultured in
supernatant from U87 cells. Real-time PCR, soluble protein,
and tube formation assays demonstrated that high expression
of miR‑145 leads to a decrease in gene, protein and functional
levels of VEGF. VEGF plays an important role in glioma
progression. An in vitro capillary tube formation assay was
employed to determine the effect of miR‑145 on angiogenesis.
Our data suggest that miR‑145 decreased capillary-like tube
formation. However, downregulation of miR‑145 reverses the
capacity of tube formation that was associated with lowered
VEGF expression. Therefore, our data suggest downregulation
of VEGF expression may be one of mechanisms by which
miR‑145 inhibits angiogenesis. We found that miR‑145 expression was inversely correlated with VEGF mRNA, in addition
to VEGF protein. This suggests that the effect of miR‑145 upon
VEGF may be indirect, rather than via translational inhibition.
It is also likely that other factors or pathways are involved in
the regulation of neovascularization. Therefore, further investigation of other signaling factors or pathways is warranted.
In our in vivo study, the data indicate that miR‑145 is a
growth inhibitor in U87 human glioma progression. Stable
transfection with a plasmid encoding miR‑145 leads to inhibition of the malignant phenotype. miR‑145 overexpression
decreased the rate of tumor growth in U87-miR‑145 glioma
bearing nude mice as compared with those parent tumor
control and negative tumor control. Downregulation of
miR‑145 promotes tumor invasion and tumor growth. These
data confirmed our in vitro result that increased miR‑145
expression decreases glioma proliferation.
ADAM17 is a primary sheddase for multiple EGFR proligands, such as HB-EGF and TGF-α (13,32). EGFR can be
activated by its ligands including EGF, TGF-α, amphiregulin,
and betacelluin (14,33). It is the first identified receptor tyrosine kinase (34). EGFR is amplified and overexpressed in
tumors of many tissues (35-37). EGFR and its downstream
signaling pathway is a key regulator of cell proliferation
and it is frequently deregulated in cancer (38,39). EGFR
ligand-binding results in receptor self-dimerization, autophosphorylation, and subsequent activation of downstream
PI3K/AKT and Ras/MAPK pathways, which are responsible
for the malignant phenotype (14,15). Furthermore, we examined the mechanisms by which ADAM17/EGFR/MAPK/
ERK pathway contributed to miR‑145-induced inhibition on
glioma proliferation, invasion, and angiogenesis after transfection of miR‑145. High expression of miR‑145 resulted in
a significant decrease in U87 cell proliferation, invasion and
angiogenesis. Coincidentally, miR‑145 overexpression deactivated ADAM17/EGFR/ERK in vitro, and downregulation of
miR‑145 increased ADAM17/EGFR/ERK activation. These
data further indicate that miR‑145 overexpression contributes
to reduction of tumor progression through deactivation of the
ADAM17/EGFR/ERK pathway.
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